Kathleen Nadine Moore

42PUBLICATIONS
240CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersPharmacogenomicsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Oct 27, 2026
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0.

|Jun 17, 2026
Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

|Dec 11, 2025
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Robert L Hollis, Austin Miller, Heather A Lankes

|Jul 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian

|Apr 07, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.

Jung-Min Lee, Austin Miller, Peter G Rose

|Jan 31, 2025
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.

Shailender Bhatia, Suzanne L Topalian, William Sharfman

Pageof 7

Frequent Collaborators

8 joint publications

Bradley J Monk

6 joint publications

Susana N Banerjee

5 joint publications

Michael Bookman

5 joint publications

Antonio González-Martín